From Screening to Precision MDT: Prof. Zhang Suzhan on the “China Solution” for Colorectal Cancer

From Screening to Precision MDT: Prof. Zhang Suzhan on the “China Solution” for Colorectal Cancer

On March 21, 2026, the Academic Seminar on Clinical Practices of Colorectal Surgery was convened in Hangzhou, Zhejiang Province. Prof. Zhang Suzhan from the Second Affiliated Hospital, Zhejiang University School of Medicine attended the meeting and shared his insights on colorectal cancer screening, precision MDT management, and localized Chinese clinical solutions.
ESMO BC Voices From China | Real-World Study From Yunnan Cancer Hospital Identifies High-Risk Features Associated With Early Rapid Progression After First-Line CDK4/6 Inhibitor Therapy in HR+/HER2− Advanced Breast Cancer

ESMO BC Voices From China | Real-World Study From Yunnan Cancer Hospital Identifies High-Risk Features Associated With Early Rapid Progression After First-Line CDK4/6 Inhibitor Therapy in HR+/HER2− Advanced Breast Cancer

CDK4/6 inhibitors combined with endocrine therapy have become the standard first-line treatment for HR-positive/HER2-negative advanced breast cancer and have significantly improved patient outcomes. However, in real-world clinical practice, a subset of patients still experiences rapid disease progression early during treatment, suggesting the presence of more aggressive tumor biology and potential intrinsic endocrine resistance mechanisms.
Sino-French Breast Reconstruction Congress | Professor Fan Li: From “One-Size-Fits-All” Surgery to Precision Remodeling—De-escalation Strategies and the Evolving Role of Breast Surgeons in the Post-Neoadjuvant Era

Sino-French Breast Reconstruction Congress | Professor Fan Li: From “One-Size-Fits-All” Surgery to Precision Remodeling—De-escalation Strategies and the Evolving Role of Breast Surgeons in the Post-Neoadjuvant Era

Against the backdrop of Chongqing’s mountainous skyline and flowing rivers, the 15th Sino-French Breast Reconstruction Congress and the 13th Sino-French Breast Cancer Academic Conference were successfully held in Chongqing from April 15–19, 2026.
ESMO BC 2026 | A Potential New First-Line “China Regimen” for Advanced TNBC: Professor Jian Zhang Reports Phase II Study of a Novel TROP2 ADC Combined With a PD-L1/VEGF-A Bispecific Antibody

ESMO BC 2026 | A Potential New First-Line “China Regimen” for Advanced TNBC: Professor Jian Zhang Reports Phase II Study of a Novel TROP2 ADC Combined With a PD-L1/VEGF-A Bispecific Antibody

On May 8, local time, at the ESMO Breast Cancer Congress 2026 (ESMO BC 2026), Professor Jian Zhang from Fudan University Shanghai Cancer Center delivered a rapid oral presentation of efficacy and safety results from the Phase II expansion cohort evaluating the PD-L1×VEGF-A bispecific antibody Pumitamig in combination with the TROP2 antibody-drug conjugate (ADC) BNT325 (sacituzumab drozuntecan) as first-line treatment for advanced or metastatic triple-negative breast cancer (a/mTNBC) (NCT05438329).
ESMO BC Voices From China | Professor Nanlin Li: Neratinib-Based Combination Therapy Opens a New Path Forward for T-DXd-Resistant HR+/HER2+ Advanced Breast Cancer

ESMO BC Voices From China | Professor Nanlin Li: Neratinib-Based Combination Therapy Opens a New Path Forward for T-DXd-Resistant HR+/HER2+ Advanced Breast Cancer

Trastuzumab deruxtecan (T-DXd) has dramatically reshaped the treatment landscape for advanced HER2-positive breast cancer because of its outstanding efficacy. It is now considered the standard second-line treatment for HER2-positive advanced breast cancer and has also demonstrated remarkable activity in both the first-line metastatic and early breast cancer settings.
47Sino-French Breast Reconstruction Congress | Professor Yongsheng Wang: From Precision Decision-Making to Standardized Training—Advancing Individualized Axillary Management

47Sino-French Breast Reconstruction Congress | Professor Yongsheng Wang: From Precision Decision-Making to Standardized Training—Advancing Individualized Axillary Management

The 15th Sino-French Breast Reconstruction Congress and the 13th Sino-French Breast Cancer Academic Conference recently concluded successfully in Chongqing. During the meeting, Professor Yongsheng Wang from Shandong Cancer Hospital delivered a presentation entitled “Precision Decision-Making in Sentinel Lymph Node Biopsy”, offering an in-depth discussion on management strategies and individualized decision pathways for sentinel lymph node biopsy (SLNB).
Sino-French Breast Reconstruction Congress | Professor Jiong Wu: Building a Replicable and Scalable “FUSCC Model” to Bring High-Quality Breast Reconstruction to More Patients

Sino-French Breast Reconstruction Congress | Professor Jiong Wu: Building a Replicable and Scalable “FUSCC Model” to Bring High-Quality Breast Reconstruction to More Patients

The 15th Sino-French Breast Reconstruction Congress and the 13th Sino-French Breast Cancer Academic Conference recently concluded successfully in Chongqing. During the meeting, Professor Jiong Wu from Fudan University Shanghai Cancer Center (FUSCC) delivered a featured presentation on the “FUSCC Model of Autologous Breast Reconstruction,” systematically outlining his center’s distinctive framework and standardized training pathway for autologous tissue breast reconstruction.
Professor Guosheng Ren & Professor Nicolas Leymarie: Rebuilding Lives, Advancing Together—Reflections and Future Perspectives on Sino-French Breast Reconstruction Collaboration | Sino-French Breast Reconstruction Congress

Professor Guosheng Ren & Professor Nicolas Leymarie: Rebuilding Lives, Advancing Together—Reflections and Future Perspectives on Sino-French Breast Reconstruction Collaboration | Sino-French Breast Reconstruction Congress

The 15th Sino-French Breast Reconstruction Congress and the 13th Sino-French Breast Cancer Academic Conference recently concluded successfully in Chongqing. As one of the long-standing academic meetings in the field of breast cancer, this year’s congress brought together leading Chinese and French experts in breast cancer treatment for live surgical demonstrations and in-depth discussions focused on oncoplastic breast-conserving surgery and breast reconstruction techniques.
2026 HOT Conference | Professor Tengfei Chao: Precision Treatment Strategies After Progression on CDK4/6 Inhibitor Plus Endocrine Therapy

2026 HOT Conference | Professor Tengfei Chao: Precision Treatment Strategies After Progression on CDK4/6 Inhibitor Plus Endocrine Therapy

From April 16–18, 2026, the 18th Northern Breast Cancer HOT Conference was successfully held in Henan Province. The meeting focused on cutting-edge advances and clinical challenges in breast cancer diagnosis and treatment, bringing together leading Chinese experts to explore new pathways toward standardized and individualized care.
ESMO BC 2026 | Academician Binghe Xu and Professor Jiayu Wang: Real-World Use of Adjuvant Abemaciclib in Chinese Patients With HR+/HER2− Early Breast Cancer

ESMO BC 2026 | Academician Binghe Xu and Professor Jiayu Wang: Real-World Use of Adjuvant Abemaciclib in Chinese Patients With HR+/HER2− Early Breast Cancer

Based on the results of the monarchE trial, abemaciclib combined with endocrine therapy (ET) has become the standard adjuvant treatment for patients with high-risk HR+/HER2− early breast cancer (EBC). However, systematic data regarding its use in routine Chinese clinical practice have remained limited.